Sarepta Therapeutics (SRPT) to Release 3-Year EMBARK Study Results on Elevidys, Stock Up 10%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: seekingalpha
- Results Announcement: Sarepta Therapeutics has announced it will release the three-year results from its EMBARK study on January 26, focusing on ambulatory Duchenne muscular dystrophy patients aged four to seven at treatment, which is expected to significantly impact the company's future market performance.
- Positive Market Reaction: Following this announcement, Sarepta's stock rose approximately 10% in after-hours trading, indicating strong investor anticipation for the upcoming data, which could influence future financing and partnership opportunities for the company.
- Webcast Scheduled: The company plans to hold a webcast and conference call at 8:30 AM ET on January 26 to further discuss the study results, providing investors with deeper insights that may affect stock price volatility.
- Market Expectations and Challenges: While there is optimism surrounding the upcoming results, previous preliminary findings did not meet market expectations, leading to cautious investor sentiment regarding Elevidys's future performance, which may impact the company's long-term strategic planning.
Analyst Views on SRPT
Wall Street analysts forecast SRPT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRPT is 20.80 USD with a low forecast of 5.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
4 Buy
10 Hold
4 Sell
Hold
Current: 21.790
Low
5.00
Averages
20.80
High
45.00
Current: 21.790
Low
5.00
Averages
20.80
High
45.00
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
